Decision-Makers’ Preferences for Approving New Medicines in Wales: A Discrete-Choice Experiment with Assessment of External Validity
A willingness to trade the cost effectiveness and QALY gains against other factors indicates that economic efficiency and QALY maximisation are not the only considerations of committee members when making recommendations on the use of medicines in Wales. On average, appraisal committee members’ stated preferences appear consistent with their actual decision-making behaviours, providing support for the external validity of our DCEs. However, as health technology assessment involves complex decision-making processes, and each individual recommendation may be influenced to varying degrees by a multitude of different considerations, the ability of our models to predict individual medicine recommendations is more limited. </AbstractSection> Copyright Springer International Publishing Switzerland 2013
Year of publication: |
2013
|
---|---|
Authors: | Linley, Warren ; Hughes, Dyfrig |
Published in: |
PharmacoEconomics. - Springer, ISSN 1170-7690. - Vol. 31.2013, 4, p. 345-355
|
Publisher: |
Springer |
Saved in:
Online Resource
Saved in favorites
Similar items by person
-
Reimbursement Decisions of the All Wales Medicines Strategy Group
Linley, Warren, (2012)
-
Estimating Drug Costs in Economic Evaluations in Ireland and the UK
Hughes, Dyfrig, (2009)
-
Resource-Use Measurement Based on Patient Recall: Issues and Challenges for Economic Evaluation
Thorn, Joanna, (2013)
- More ...